| Viloxazine extended-release (ER) is under investigation as a non-stimulant treatment for attention-deficit/hyperactivity disorder and could be coadministered with other medications. |
| Viloxazine ER and methylphenidate were coadministered and the potential for pharmacokinetic interactions was evaluated. |
| Coadministration of viloxazine ER with methylphenidate did not impact the pharmacokinetics of either drug alone, and the combination appeared to be safe and well-tolerated. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.